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Abstract: This review focuses on active clinical research in pediatric
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clinical research that could successfully be conducted through the
SPLIT collaborative and would have signiﬁcant impact in pediatric
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has evolved from a research registry into a multi-
faceted organization focused on improving
outcomes for children receiving liver transplanta-
tion. The original support for registry develop-
ment and data collection was provided by
industry partners with interest in the area of
transplantation. The focus at that time was on
collecting descriptive data regarding candidate
characteristics, surgical approaches, and key out-
comes including patient and graft survival, rejec-
tion and vascular complications. The data were
designed to be more comprehensive than what
was collected for the United Network for Organ
Sharing and the data collection extended into
long-term follow-up.
As registry participation and the patient cohort
grew, leaders of the SPLIT Research group devel-
oped a set of aims and hypotheses for ongoing
research that were informed by early registry ﬁnd-
ings. These aims became the core of a proposal
that was funded by the NIDDK as a ﬁve-yr con-
sortium grant, during which time 1334 transplant
recipients were newly enrolled. Federal funding of
the consortia extended for a six-yr period, and
analyses of registry data resulted in 22 peer
reviewed publications. At the peak of enrollment,
the registry included 45 centers in the United
States and Canada, and data collection was cap-
tured for approximately 71% of the pediatric liver
transplants that occurred each year in North
America. Data collected during this time period
form an important repository that will inform
decisions in pediatric transplantation for many
years to come.
In 2009, the research group underwent a
transformative period realigning their priorities
and funding mechanisms to meet current chal-
lenges in health outcomes research. During this
transformation, the group’s goals were extended
beyond that of clinical research to embrace the
missions of clinician education and patient
advocacy. The group now continues to collect
abbreviated registry data on newly transplanted
patients and long-term follow-up information
for patients in the existing cohort at currently
participating SPLIT centers. Current research
questions focus on quality initiatives, and data
collection is tailored on an ongoing basis to sup-
port current research questions and priorities.
The existing registry allows participating investi-
gators to easily identify potential candidates for
intervention trials and thus provides a valuable
infrastructure for new grant development. Each
participating center contributes funding to sup-
port the data coordinating center and under-
writes the eﬀorts of research coordinators and
nurses to submit data.
The purpose of this document is to deﬁne
research priorities for the SPLIT group as the
eﬀort moves forward. This review focuses on
active clinical research in pediatric liver trans-
plantation with special emphasis on areas that
could beneﬁt from studies utilizing the SPLIT
infrastructure and data repository. Ideas were
solicited by members of the SPLIT Research
Committee, and sections were drafted by
members of the committee with expertise in those
given areas. This review is intended to highlight
priorities for clinical research that could
successfully be conducted through the SPLIT
collaborative and would have signiﬁcant impact
in pediatric liver transplantation.
Strategies to improve early graft function
Development of a pediatric-specific DRI
The development of the concept of a DRI in liver
transplantation represented an advance in the
ﬁeld as it clearly deﬁned donor characteristics
that were associated with future allograft sur-
vival (1). Equally as important, it formed a foun-
dation for other studies that have signiﬁcantly
advanced the ﬁeld. While the DRI is an impor-
tant variable in liver transplantation, it does have
clear limitations. For example, despite the
increasing epidemic of non-alcoholic fatty liver
disease, there is currently no clearly deﬁned
mechanism in which to incorporate hepatic
steatosis into the DRI. Further, compared with
candidate disease severity, donor quality is only
a relative consideration. A donor with an unac-
ceptably high DRI for a patient with a relatively
low MELD score may be a perfectly appropriate
option and oﬀer a signiﬁcant survival advantage
for a patient with a higher MELD score (2).
Many of the variables included in the DRI
have been discussed in the pediatric liver trans-
plant literature. For example, donor age and
the use of technical variant allografts have been
shown by many authors to carry an increased
relative risk of graft failure in children (3–5).
However, these risks are only a relative
consideration compared with recipient disease
severity. While the global DRI, in general, can
be adopted for the pediatric population, the
ﬁdelity of prediction likely decreases. In addi-
tion, given the many unique pediatric diseases
treated with liver transplantation, the develop-
ment of a pediatric-speciﬁc DRI is an identiﬁ-
able need. The SPLIT Research group is ideally
poised to support such a research project. The
ability to deﬁne multiple donor variables
matched to pediatric-speciﬁc problems such as
recipient size, diagnoses, and disease severity
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can more clearly deﬁne the combination of
donor and recipient outcome predictors.
One advantage of a pediatric-speciﬁc DRI is
the ability to better predict early allograft func-
tion. There are many reasons to devote research
eﬀort toward improvements in this area. First
and foremost is the improvement of graft func-
tion and survival in pediatric recipients. In this
area, a better understanding of the relationship
between immediate allograft function and long-
term graft and patient survival would be useful.
Second, it is clear that allografts with delayed
functional recovery lead to increased resource
utilization and increased costs. The ability to pre-
dict early functional recovery of an allograft is
an area in which the SPLIT study group should
strive to involve basic and translational science
into DRI predictions. Much like the develop-
ment of a reliable steatosis predictor could
improve the adult DRI, incorporation of a mea-
surable physiologic donor metric or a serum bio-
marker of liver injury will signiﬁcantly increase
the ﬁdelity of any pediatric-speciﬁc DRI.
Potential research projects
1 Registry-driven study to determine donor risk
factors that determine early allograft function
in pediatric liver transplant recipients with
emphasis on factors that are important to the
function of technical variant grafts. Such an
analysis would evaluate the relative impact of
such factors across diﬀerent recipient disease
states.
Technical complications following pediatric liver
transplantation
Much is written about complications following
pediatric liver transplantation. The reported
rates vary greatly depending on the time of fol-
low-up reported, the type of allograft used, and
the age/size of the recipient. A recent report from
the SPLIT study group oﬀers the sobering statis-
tic that 71.4% of pediatric recipients of a whole
organ liver transplant will have a complication
within two yr of transplant. This percentage
grows as high as 86.9% for recipients of technical
variant allografts (4). While these statistics incor-
porate many measured complications, biliary,
vascular, and GI complications are major
contributors to post-transplant morbidity in
pediatric recipients. There are many studies in
the current literature describing single-center
approaches to many of these complications;
however, there are little prospective data evaluat-
ing various strategies designed to prevent or treat
these complications.
A review of the literature regarding vascular
thrombosis following pediatric liver transplanta-
tion reveals myriad manuscripts discussing the
use of operating microscope vs. loupe magniﬁca-
tion, the use of diﬀering techniques of vascular
reconstruction, routine vs. selective use of
Doppler ultrasound, and the use of various anti-
coagulation protocols. Given that these are usu-
ally single-center studies with varying baseline
rates of vascular thrombotic complications and
diﬀering patient demographics (age/size), it is
diﬃcult to determine a “best practice” strategy.
The average rate of HAT at centers participat-
ing in the SPLIT study group is between 4%
and 9% (4), and it is diﬃcult to imagine being
able to demonstrate a signiﬁcant reduction in
rates of HAT without involving multiple centers
in a cooperative eﬀort. For this and other rea-
sons, the SPLIT study group is uniquely poised
to be the leader in this eﬀort.
Similar analogies can be made for biliary com-
plications which have a much higher occurrence,
especially in recipients of technical variant allo-
grafts (4, 6). Given that the rates of these types
of technical complications have changed little in
the last 10 yr, coordinated, multicenter studies
addressing these problems in pediatric liver
transplantation will be needed to advance the
ﬁeld. These studies will ideally be a combination
of clinical, basic, and translational science.
Potential research projects
1 Randomized trial of anticoagulation protocols
measuring the combined end points of portal
vein or hepatic arterial thrombosis and
re-exploration for intraperitoneal bleeding
within the ﬁrst 72 h following reperfusion.
Designing such a study would require a careful
survey of standard practices across SPLIT cen-
ters with the expectation that some form of
therapy is standard. Thus, the study would
randomize patients to receive one of two com-
monly used protocols to compare the risks and
beneﬁts.
2 Longitudinal analysis of outcomes following
percutaneous treatment of biliary strictures.
Such a study could be conducted as an obser-
vational analysis with the primary end point
being clinical evidence of stricture recurrence
in 36 months following initial therapy. The
analysis would examine method and duration
of stent placement, currently not standardized,
as predictors of the outcome. Risks would be
adjusted for primary diagnosis, type of graft,
history of hepatic arterial complication, and
area of stricture (anastomosis vs. intrahepat-
ic).
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Reﬁning indications for transplant in special populations
Hepatic malignancy in children
The two most common malignant liver tumors in
children are HB and HCC. In patients diagnosed
with HB, the standard treatment algorithm
employs neoadjuvant chemotherapy followed by
resection; however, in a subgroup of patients,
tumor burden precludes conventional resection.
In this subgroup, liver transplantation is used to
achieve local control. In children diagnosed with
HCC, the role of chemotherapy remains contro-
versial; complete local control by conventional
resection or liver transplantation is the only
route to achieve long-term cure. Ongoing eﬀorts
by the COG and the SIOPEL to identify the
appropriate indications for transplantation could
be enhanced with additional research eﬀorts
conducted by the SPLIT consortium.
Hepatoblastoma
HB accounts for about 80% of the malignant liver
tumors in children. The incidence has increased
from 0.6 to 0.8 per million to 1.2–1.5 per million
over the past two decades (7, 8). PRETEXT, a
staging system devised by the SIOPEL in the
1990s (9) and revised for SIOPEL 3 in 2007 (10),
is based on cross-sectional imaging of the extent
of tumor, and assignment to one of the four PRE-
TEXT groups (PRETEXT I, II, III, or IV) is
determined by the number of contiguous unin-
volved sections of the liver. PRETEXT is further
annotated with a V, P, E, M, or C depending
upon extension of tumor beyond the hepatic
parenchyma of the major sections. In the current
trials, surgical resection guidelines use PRETEXT
to deﬁne which tumors should be resected at diag-
nosis, receive neoadjuvant chemotherapy, and
which should be referred for possible liver trans-
plantation. Complete eradication of tumor is a
prerequisite for cure which makes an aggressive
surgical approach necessary and highlights one of
the advantages of primary transplantation. Con-
trary to earlier trials where decisions about surgi-
cal resection were made by individual surgeons,
the surgical guidelines of the current COG trials
use PRETEXT to deﬁne the timing and extent of
surgical resection, the use of neoadjuvant chemo-
therapy, and indications for liver transplantation.
Resection at diagnosis is recommended only when
a segmentectomy or non-extended lobectomy will
predictably yield a complete resection, and neoad-
juvant therapy is given prior to resection of PRE-
TEXT III tumors. Alternatively, in the European
SIOPEL and GPOH study groups, neoadjuvant
chemotherapy is given to all patients with the rare
patient going directly to transplant depending
upon the recommendation of the transplant cen-
ter.
After the pioneering work of Reyes, Superina,
and Al Qabandi in the late 1990s (11–13), trans-
plantation has become a critical component of
the treatment algorithm of HB. Long-term
survival ranging from 55% to 100% has been
reported over the past decade in over a dozen
single centers. Cases of “unresectable” HB due to
involvement of the entire liver, extensive multifo-
cality, or major hepatic venous or portal venous
involvement comprise 10–20% of all HB treated
in multicenter trials. The best results for high-
risk HB reported to date were in SIOPEL 3 (14),
and the improvement in outcome seen in this
study appears to be at least partly due to an
increase in the use of liver transplant. Multiple
series have shown superior outcome with
primary transplant (about 80% overall survival)
compared with rescue transplant (about 30–40%
overall) (15–20). The basis for this is undoubt-
edly multifactorial, but two important concerns
are the likelihood of chemotherapy resistance in
relapse tumors (21, 22), and the debilitated state
of the patients when transplanted in the face of
end-stage disease.
SIOPEL, together with support from COG,
GPOH, SPLIT, and individual pediatric liver
transplant centers all over the world, has
established a worldwide electronic registry for
liver transplant for childhood tumors (HB,
HCC, infantile hemangioma, and others) titled
the PLUTO (23). This collaboration will allow
assessment of outcomes across an international
cohort and could provide infrastructure for valu-
able treatment trials that explore the beneﬁts of
LT in children with extensive HB.
Hepatocellular carcinoma
HCC occurs predominantly in the setting of
underlying liver disease and cirrhosis. However,
de novo tumors without underlying cirrhosis are
more common in children than adults (24). More
than two-thirds of pediatric HCC occur in chil-
dren older than 10 yr of age, but only 0.5–1% of
all HCC manifest before 20 yr of age. Very few
HCCs are diagnosed in children less than ﬁve yr
old, and in this young age group, transitional-
type tumors are seen. About 20–35% of children
with HCC have underlying chronic liver disease.
It is still disputed whether “adult-type” HCC in
children is the same or a diﬀerent disease. Zim-
mermann and others have suggested that HCC
forms a tumor family, consisting of adult-type
HCC and its variants, ﬁbrolamellar HCC, and a
415
SPLIT Research Agenda 2013
novel entity occurring in young children and
adolescents, TLCT (25, 26).
No staging or grading system has been found
that accurately predicts prognosis in pediatric
HCC. In the pediatric multicenter trials, HCC
has been usually treated using the same proto-
cols, but analyzed separately. PRETEXT has
been used because of its utility in HB and the
crossover between these two tumors in the inter-
mediate age group. HCC is relatively chemoresis-
tant and therefore carries a poor prognosis with
a dismal cure rate (27, 28). Complete surgical
resection or transplantation of tumor localized
to the liver is often the only hope. Unfortunately,
HCC is most often advanced at diagnosis and
cure is rarely possible in the setting of metastatic
disease. The main prognostic factor for child-
hood HCC is resectability.
The role of liver transplantation in pediatric
HCC is in greater evolution than in pediatric
HB. Liver transplant is contraindicated in the
presence of any extrahepatic tumor, even in the
occasional patient who regresses with chemother-
apy. Some argue an exception might be made in
the intermediate case of children with TLCT.
Outcome for transplant in adult HCC has
improved over the years due to the recognition
that strict selection criteria are important in
preventing post-transplant tumor relapse. The
Milan criteria, introduced by Mazzaferro in 1996
for adults with advanced cirrhotic liver disease,
were developed for a patient population, who
develop tumor nodules (usually multiple) as part
of their cirrhotic (often alcoholic) liver disease.
The Milan criteria restrict transplant for HCC in
adults to: (i) single tumor < 5 cm; (ii) not more
than three nodules; (iii) no angioinvasion; (iv) no
extrahepatic involvement (29). The problem with
applying the Milan criteria to children is that 50–
70% of children present with large de novo
tumors in an otherwise healthy (non-cirrhotic)
liver. These de novo tumors in non-cirrhotic livers
in children are felt to exist on a continuum with
transitional cell tumors and HB, and seem to
have a diﬀerent biology (30), at the very least
they have a very diﬀerent epidemiology. Two
recent series of pediatric liver transplant ques-
tioned the relevance of Milan criteria to pediatric
HCC. In a series from Stanford, 10 children were
transplanted for HCC and neither the number of
tumors, nor the size of tumor, nor the presence
of gross vascular invasion was correlated with
the risk of post-transplant tumor relapse (31). Of
the four Milan criteria evaluated in children in a
transplant series from Poland: three children did
not fulﬁll four criteria; three children did not ful-
ﬁll two criteria; and two children did not fulﬁll
one criterion (32). Thus, it is unclear whether
children with HCC should be limited to the same
treatment options oﬀered to adults (33).
Potential research projects.
In the current protocols conducted by COG and
SIOPEL, liver transplantation is the end point of
the algorithm. The goal of PLUTO is to begin to
describe the outcomes following transplantation;
however, as a registry, it faces inherent chal-
lenges. In that respect, there are multiple oppor-
tunities for the SPLIT consortium to contribute.
These include:
1 Registration of all patients transplanted for
hepatic malignancy at SPLIT centers into the
PLUTO registry to coordinate longitudinal
observational studies.
2 Prospective randomized trials evaluating the
role of immunosuppression in the context of
chemotherapy.
3 Outcomes comparisons between conventional
resection vs. liver transplantation to deﬁne the
beneﬁts of transplantation.
Issues in maintenance of long-term graft function
Tolerance in pediatric liver transplantation
Pediatric liver transplant recipients are at risk to
develop multiple complications related to long-
term exposure to IS. These complications include
immune and non-immune related illnesses, many
of which could be life threatening (opportunistic
infection and PTLD) or lead to chronic disease
that can limit the patient’s life span (renal insuﬃ-
ciency and diabetes).
Single-center experiences in which patients are
withdrawn from immunosuppression due to
medical complications such as PTLD or renal
insuﬃciency suggest that approximately 20% of
LT recipients are functionally tolerant. Experi-
ence at the University of Pittsburgh (both pub-
lished and unpublished) suggests a higher success
rate for pediatric recipients with an observed
operational tolerance rate in 22 (34%) of 64
recipients (34). The Kyoto University transplant
program has similarly reported that 15% of their
entire, unselected cohort of 581 pediatric living
donor liver recipients has been withdrawn from
IS with <1% of patients developing obvious
chronic rejection (35, 36). This experience
informed a recent phase I trial conducted
through the ITN in which 20 pediatric LT recipi-
ents of parental living donor transplant were
withdrawn from immunosuppression over a 12-
month period. In this trial, 12 of the 20 patients
remain oﬀ IS at 20–41 months with stable graft
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function and no histological evidence of chronic
rejection and no episodes of graft loss (37). As a
safety study, this trial did not include a control
arm and was not powered to examine signiﬁcant
changes in histology over time. Although acute
cellular rejection was not diagnosed in the toler-
ant group, many had liver dysfunction and mild
inﬂammatory changes on liver biopsy. Inclusion
of a control arm and examination of a larger
sample size in future studies are essential to
determine the durability of tolerance in this
group and better deﬁne inﬂammatory and aﬁb-
rotic changes in the grafts over time.
Ongoing tolerance trials are dependent upon
the principle that acute rejection episodes can
be easily reversed without permanent injury
to the graft. Current IS withdrawal or minimiza-
tion study designs employ a “trial and error”
approach, gradually eliminating IS until the
patient develops signs of acute rejection. Wide-
spread clinical application of IS withdrawal will
depend upon the ability to reliably predict which
patients will develop operational tolerance, thus
minimizing the risk of acute rejection (38). Clini-
cal (interval from transplant) and histological
features (lack of graft inﬂammatory changes)
suggest a phenotype of patient most likely to
safely withdraw from IS, but there are no
accepted methods to monitor the patient’s func-
tional immune status or level of reactivity to the
liver allograft (39). Identiﬁcation of a reproduc-
ible ﬁngerprint of operational tolerance is a pre-
requisite for broad application of IS drug
withdrawal in liver transplant recipients. Even
though many immune monitoring techniques
have been developed with potential to detect
active mechanisms of immune tolerance or pre-
clinical signs of allograft rejection, no assay has
been prospectively shown to serve as a robust
biomarker of operational tolerance.
Potential research projects
1 Randomized controlled trial of IS withdrawal
in pediatric patients. Such a study would
include collection of biospecimens for immune
monitoring and serial liver histology (see
below). Analysis of clinical predictors of toler-
ance would be included as well. Similar to this,
iWITH is a recently launched multicenter,
open label, longitudinal, phase II clinical trial
to determine the safety and eﬃcacy of immu-
nosuppression withdrawal with concomitant
portfolio of translational studies to develop
and validate a ﬁngerprint which predicts oper-
ational tolerance. This study currently involves
11 pediatric liver transplant centers/clinical sites
in the United States and Canada. The primary
goal of this study is to test the hypothesis that a
deﬁned subset of stable pediatric liver transplant
recipients can safely and durably withdraw from
immunosuppression (37).
2 Large-scale (sample size 150–200 patients)
study to examine histological response to
immunosuppression withdrawal which includes
a control arm and allows histological compari-
sons over time.
3 Development of immune monitoring techniques
to identify tolerant patients.
Long-term graft injury after pediatric liver transplantation
Histological abnormalities are commonly pres-
ent in late post-transplant biopsies, including
protocol biopsies from patients who appear to
be well with good graft function. Some of the
abnormalities seen include rejection (which
may have a diﬀerent appearance from rejection
seen in the early post-transplant period), de
novo disease, idiopathic post-transplant allograft
hepatitis, allograft ﬁbrosis, nodular regenerative
hyperplasia, vascular anomalies, and recurrent dis-
ease. The prevalence and spectrum of changes
reported in these long-term biopsies varies between
diﬀerent transplant centers. This diﬀerence may be
reﬂective of center-speciﬁc immunosuppression
practice, as well as diﬀerences in the terminology
used to describe changes of uncertain etiology in
late biopsies.
The use of protocol biopsies has changed in
recent years. While most centers use protocol
biopsies to assess disease progression in chronic
hepatitis C for instance, the majority have
discontinued this practice in other transplant
recipients. However, numerous studies have
shown that histological abnormalities are not
only frequently seen in protocol biopsies from
recipients with normal liver enzymes (40, 41),
but some of these abnormalities are potentially
signiﬁcant (40, 42–44).
Potential research projects
1 Longitudinal analysis of protocol biopsy ﬁnd-
ings in patients on minimal immunosuppres-
sion, i.e., once daily calcineurin inhibitors or
rapamycin. This should include histological
analysis of bile duct atypia/atrophy/focal loss
or ﬁbrosis.
2 Longitudinal analysis of the evolution of patients
with allograft hepatitis, especially those classiﬁed
as de novo alloimmune hepatitis.
3 The development of optimal algorithms for
the use of liver biopsy in the assessment of the
long-term liver allograft.
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Improving health for the long-term survivor
Long-term medical complications after pediatric liver
transplantation
Long-term survival after pediatric liver trans-
plantation is the rule rather than the exception.
Patients and families and healthcare providers
face major challenges particularly related to the
life-long immunosuppression and follow up
currently necessary post-transplant (45). These
challenges pertain to both the numerous immune-
and non-immune-mediated complications, risks of
both over- and under-immunosuppression, as well
as the “uncharted territory” of current practice of
life-long immunosuppression required by our
patients. Indeed, less than one-third (32%) of
patients achieved an “ideal” proﬁle of a ﬁrst allo-
graft stable on immunosuppression monotherapy,
normal growth, and absence of common immu-
nosuppression-induced sequelae (46). Multiple
published, in press, and in preparation SPLIT
manuscripts provide most commonly a cross-sec-
tional study analyses of some of these long-term
medical complications (47–52).
While liver transplant programs still need to
pay critical attention to short-term survival, the
need to develop strategies which will further
increase the proportion of “perfect patients” and
decrease late allograft dysfunction (chronic hepa-
titis, ﬁbrosis, and biliary “misery”) is paramount.
These eﬀorts and other opportunities will ideally
require the whole arsenal of clinical, basic, and
translational science. Directed toward the
prevention of complications, mitigation of early
processes, and rescue of existing complications,
this research calls for collaboration, energy, and
strategies among individual SPLIT centers.
Potential research projects
1 Longitudinal assessment of outcomes for pedi-
atric liver transplant recipients which couples
clinical data acquisition with biological speci-
men collection. Such endeavors would require
consistent and uniform approaches to data
and specimen collection to enable the desired
goal of well-characterized long-term patient
cohorts, possibly extending such tracking into
early adulthood, analogous to what has been
done for cancer survivors.
2 Longitudinal observational studies of the rela-
tionship between cardiovascular risk/outcomes
and immunosuppression medications. Poten-
tial considerations include: (i) linking risk
factors for cardiovascular disease to abnor-
malities in intermediate end points such as
arterial stiﬀness and carotid intima media
thickness which may permit focused interven-
tions in high-risk patients before development
of clinical disease; (ii) earliest evaluation and
potential treatment (whether directed lifestyle
modiﬁcation or pharmacological therapies)
may be key to ensuring best outcomes; and
(iii) metabolic syndrome.
3 Development of models to predict post-trans-
plant renal function that include factors related
to phenotype such as underlying renal disease
and genetic polymorphisms that impact calci-
neurin inhibitor pharmacodynamics.
4 Risk assessment of post-transplant malignan-
cies which might help deﬁne screening
guidelines for malignancies in pediatric LT
recipients. Recent SPLIT cross-sectional anal-
yses might serve as background and pilot data
for speciﬁc initiatives.
5 Assessment of the impact of chronic anemia
on health status and fatigue.
6 Assessment and evaluation of health-related
quality of life in selected patient cohorts
including possibly adult survivors of pediatric
liver transplantation.
Transition and adolescent issues after pediatric liver
transplantation
The adolescent developmental period is charac-
terized by change in cognitions, emotional
attachments, physical development, indepen-
dence, education/vocation, and self-identity. This
stage of development is a critical period for the
establishment of both lifelong positive and risky
health-related behaviors. With respect to chronic
illness, disease management, including medica-
tion adherence, is often at odds with typical
adolescent development (53, 54). The develop-
mental characteristics associated with adoles-
cence, including developing autonomy from
family, assimilating with peers and separating
from parents, poorly developed abstract thinking
and understanding long-term consequences of
present actions, are often diﬃcult to balance with
the behaviors required for optimal medication
adherence (55).
The prevalence of non-adherence among pedi-
atric transplant recipients ranges from 5 to 80%,
with adolescents having the highest rates of non-
adherence (56–58). These rates of non-adherence
are striking given the potential for serious conse-
quences including graft rejection, graft loss, post-
transplant mortality, poor health-related quality
of life, and increased healthcare costs (59–63).
Medication non-adherence has also been impli-
cated in poor health outcomes following the
transfer from pediatric to adult-centered care
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(64). Given that adolescents are at high risk of
non-adherence and associated late graft dysfunc-
tion, interventions aimed at promoting medica-
tion adherence in this population are urgently
needed.
Yet, before interventions targeting adherence
can be implemented, it is necessary to incorpo-
rate adherence assessment into standard clinical
care (65). Unfortunately, to date, studies of med-
ication adherence in pediatric transplantation are
limited by a lack of an accepted “gold standard”
method for assessing adherence. Recent studies
have attempted to measure adherence objectively
using the degree of ﬂuctuation (i.e., standard
deviation, s.d.) of medication blood levels of
tacrolimus in pediatric liver transplant recipients
(59, 66–68). Higher s.d.s were predictive of clini-
cal outcomes, such as biopsy-proven rejection
and hospitalizations.
“Transition” is an active process that addresses
the medical, psychosocial, and educational/voca-
tional needs of adolescents as they prepare to
move from child- to adult-centered health care
(69), while “transfer” refers to the change in the
location where care is provided (70, 71). The tran-
sition process is twofold as it includes the transi-
tion of responsibility for healthcare tasks from the
parent to the patient, as well as the preparation to
transfer to adult-centered care. Beginning in late
childhood/early adolescence, the management of
a chronic illness begins to shift from the primary
responsibility of the parent to self-management by
the adolescent (72–74). By shifting responsibility
for health-related tasks in a developmentally
appropriate manner, the adolescent gains the
knowledge, skills, and experiences necessary to
master the independence required to be successful
in the adult healthcare system.
Self-management skills are integral to the
achievement of independence necessary for suc-
cessful healthcare transitions (73, 75). Research-
ers and clinicians agree that adolescents and
young adults should not transfer from pediatric
to adult health services unless they have the skills
necessary for functioning eﬀectively in the adult
healthcare system, including adhering to medica-
tion regimens (75, 76). The Pediatric Committee
of the American Society of Transplantation has
recommended that prior to transferring to adult-
centered care, the pediatric transplant recipient
should demonstrate the ability to independently
manage their health (77). In addition, the pediat-
ric patient should adhere to their immunosup-
pressant medications to avoid increased risk of
graft loss and rejection following the transfer to
adult-centered care (63, 64).
Potential research projects
Adolescent issues.
1 Assessment of the impact of executive func-
tioning on medication adherence and transi-
tion readiness among adolescents.
Transition planning.
1 There is a critical need for the development
and validation of objective assessment tools to
empirically evaluate the pediatric patient’s
readiness to move from a pediatric to adult-
focused transplant health care. Transition
readiness assessment tools should evaluate reg-
imen knowledge, allocation of responsibility
for healthcare tasks, self-management skills,
and adherence.
2 Assessment of the impact of healthcare transi-
tion on measures of patient satisfaction,
medical stability, quality of life, psychosocial
functioning, educational/vocational outcomes,
and healthcare utilization rates.
3 The timing of transfer from pediatric to
adult-focused care should be individualized
and based on the acquisition and mastery of
self-management skills. Thus, research is
needed to develop benchmarks to guide in
determining the individualization of transfer
to adult-centered care. The development of
transition planning curricula and guidelines
should include collaboration with the adoles-
cent/young adult recipients and parents to
determine how to best provide them with
information related to the transition process.
4 Research is needed to deﬁne and identify pre-
dictors of successful transition to inform the
development of programs which target modiﬁ-
able factors. Research is needed to identify a
standard transition practice for transplant pro-
viders to follow to enhance communication
and collaboration between pediatric and adult
caregivers during the transitional period.
5 Research investigating the role of health liter-
acy and patient education in the transition
process is also warranted.
Adherence promotion and self-management inter-
ventions.
1 Future studies should continue to focus on
developing a standardized method for rou-
tinely assessing medication adherence in pedi-
atric liver transplant recipients.
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2 The development of empirically based inter-
ventions to promote self-management skills is
critical. Interventions should also target paren-
tal monitoring and the transition of responsi-
bility of health-related tasks from the parent
to the adolescent/young adult. Thus, interven-
tions should focus on the role of parental mon-
itoring and supervision of medication-related
tasks as adolescents begin to demonstrate mas-
tery of health management tasks.
3 Healthcare providers are responsible for the
delivery of health-related information, foster-
ing motivation, assisting their patients with the
behavioral skills necessary for adherence, and
collaborating on plans for chronic illness man-
agement. Future research should examine the
impact of physician communication and moti-
vational strategies on medication adherence in
adolescents.
4 Interventions delivered using newer technolo-
gies, such as cell phone text messages and the
internet, may be promising for promoting
medication adherence in adolescents. Further
investigation of the sustainability and eﬀec-
tiveness of these innovative eHealth interven-
tions is needed.
Summary
Great strides have been made in improving
health outcomes in recipients of pediatric liver
transplantation in the past 15 yr. The SPLIT
Research group has been an invaluable spring
board and infrastructure to support analyses that
have informed and transformed care of this com-
plex patient group. With the shifting sands of
clinical research funding, the SPLIT group has
reorganized to meet current challenges and con-
tinue in their mission to inspire and support
innovative studies and initiatives to improve
patient care.
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